JP2015520130A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520130A5 JP2015520130A5 JP2015507101A JP2015507101A JP2015520130A5 JP 2015520130 A5 JP2015520130 A5 JP 2015520130A5 JP 2015507101 A JP2015507101 A JP 2015507101A JP 2015507101 A JP2015507101 A JP 2015507101A JP 2015520130 A5 JP2015520130 A5 JP 2015520130A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- substituted
- unsubstituted
- methyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 32
- 239000001257 hydrogen Substances 0.000 claims 32
- -1 Diethyl ({[(2S) -2-({[(4-bromophenyl) amino] carbonyl} amino) -4-methylpentanoyl] amino} methyl) phosphonate Chemical compound 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 150000002431 hydrogen Chemical class 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 208000017442 Retinal disease Diseases 0.000 claims 5
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010038910 Retinitis Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 210000001927 retinal artery Anatomy 0.000 claims 3
- 230000002207 retinal effect Effects 0.000 claims 3
- 208000004644 retinal vein occlusion Diseases 0.000 claims 3
- WCGZSGWHOKVWEC-AWEZNQCLSA-N (2s)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-n-[(3-oxo-1,2-oxazol-5-yl)methyl]pentanamide Chemical compound N([C@@H](CC(C)C)C(=O)NCC=1ON=C(O)C=1)C(=O)NC1=CC=C(Br)C=C1 WCGZSGWHOKVWEC-AWEZNQCLSA-N 0.000 claims 2
- SJBYUKPOGWWLGD-SFHVURJKSA-N (2s)-2-[(4-bromophenyl)carbamoylamino]-n-[di(propan-2-yloxy)phosphorylmethyl]-4-methylpentanamide Chemical compound CC(C)OP(=O)(OC(C)C)CNC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 SJBYUKPOGWWLGD-SFHVURJKSA-N 0.000 claims 2
- OHDBESLRXKFIOM-KRWDZBQOSA-N (2s)-2-[(4-bromophenyl)carbamoylamino]-n-[di(propan-2-yloxy)phosphorylmethyl]pentanamide Chemical compound CC(C)OP(=O)(OC(C)C)CNC(=O)[C@H](CCC)NC(=O)NC1=CC=C(Br)C=C1 OHDBESLRXKFIOM-KRWDZBQOSA-N 0.000 claims 2
- JFQFHPOCFBTXQU-LBPRGKRZSA-N (2s)-4-methyl-n-(2h-tetrazol-5-ylmethyl)-2-[[4-(trifluoromethyl)phenyl]carbamoylamino]pentanamide Chemical compound N([C@@H](CC(C)C)C(=O)NCC=1NN=NN=1)C(=O)NC1=CC=C(C(F)(F)F)C=C1 JFQFHPOCFBTXQU-LBPRGKRZSA-N 0.000 claims 2
- OXUDSYTWELPSGA-INIZCTEOSA-N (2s)-n-(diethoxyphosphorylmethyl)-4-methyl-2-[[4-(trifluoromethyl)phenyl]carbamoylamino]pentanamide Chemical compound CCOP(=O)(OCC)CNC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(C(F)(F)F)C=C1 OXUDSYTWELPSGA-INIZCTEOSA-N 0.000 claims 2
- 208000014882 Carotid artery disease Diseases 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000002367 Retinal Perforations Diseases 0.000 claims 2
- 201000007737 Retinal degeneration Diseases 0.000 claims 2
- 206010038848 Retinal detachment Diseases 0.000 claims 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims 2
- 208000029977 White Dot Syndromes Diseases 0.000 claims 2
- PEHBGUYWYZGJBH-HNNXBMFYSA-N [[(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methylpentanoyl]amino]methyl-propan-2-yloxyphosphinic acid Chemical compound CC(C)OP(O)(=O)CNC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 PEHBGUYWYZGJBH-HNNXBMFYSA-N 0.000 claims 2
- MOQSGUOBKDNQHO-LBPRGKRZSA-N [[(2s)-2-[(4-bromophenyl)carbamoylamino]-4-methylpentanoyl]amino]methanesulfonic acid Chemical compound OS(=O)(=O)CNC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 MOQSGUOBKDNQHO-LBPRGKRZSA-N 0.000 claims 2
- IQDHSPTVDPEENI-LBPRGKRZSA-N [[(2s)-4-methyl-2-[[4-(trifluoromethyl)phenyl]carbamoylamino]pentanoyl]amino]methanesulfonic acid Chemical compound OS(=O)(=O)CNC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(C(F)(F)F)C=C1 IQDHSPTVDPEENI-LBPRGKRZSA-N 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 210000001525 retina Anatomy 0.000 claims 2
- 230000004264 retinal detachment Effects 0.000 claims 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims 2
- 208000006379 syphilis Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- IZJUGUJPXFXTQE-KRWDZBQOSA-N (2s)-n-(diethoxyphosphorylmethyl)-4-methyl-2-[(4-methylsulfanylphenyl)carbamoylamino]pentanamide Chemical compound CCOP(=O)(OCC)CNC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(SC)C=C1 IZJUGUJPXFXTQE-KRWDZBQOSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 201000007795 Bietti crystalline corneoretinal dystrophy Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010070957 Choroidal haemangioma Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims 1
- 208000021089 Coats disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 208000019878 Eales disease Diseases 0.000 claims 1
- 208000001351 Epiretinal Membrane Diseases 0.000 claims 1
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 claims 1
- 206010018612 Gonorrhoea Diseases 0.000 claims 1
- 208000002927 Hamartoma Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 208000005100 Herpetic Keratitis Diseases 0.000 claims 1
- 241000228402 Histoplasma Species 0.000 claims 1
- 201000002563 Histoplasmosis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000032578 Inherited retinal disease Diseases 0.000 claims 1
- 206010022557 Intermediate uveitis Diseases 0.000 claims 1
- 201000000512 Intraocular Lymphoma Diseases 0.000 claims 1
- 208000034693 Laceration Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 208000031471 Macular fibrosis Diseases 0.000 claims 1
- 208000024556 Mendelian disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000010164 Multifocal Choroiditis Diseases 0.000 claims 1
- 208000001140 Night Blindness Diseases 0.000 claims 1
- 206010065700 Ocular sarcoidosis Diseases 0.000 claims 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 208000034247 Pattern dystrophy Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 208000034461 Progressive cone dystrophy Diseases 0.000 claims 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010064714 Radiation retinopathy Diseases 0.000 claims 1
- 208000008709 Retinal Telangiectasis Diseases 0.000 claims 1
- 206010038821 Retinal anomaly congenital Diseases 0.000 claims 1
- 201000007527 Retinal artery occlusion Diseases 0.000 claims 1
- 208000032430 Retinal dystrophy Diseases 0.000 claims 1
- 208000032398 Retinal pigment epitheliopathy Diseases 0.000 claims 1
- 206010038897 Retinal tear Diseases 0.000 claims 1
- 206010038899 Retinal telangiectasia Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010038915 Retinitis viral Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims 1
- 206010038997 Retroviral infections Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000027073 Stargardt disease Diseases 0.000 claims 1
- 208000036038 Subretinal fibrosis Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 235000011941 Tilia x europaea Nutrition 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000023564 acute macular neuroretinopathy Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 206010072959 birdshot chorioretinopathy Diseases 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 201000005849 central retinal artery occlusion Diseases 0.000 claims 1
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 1
- 210000003161 choroid Anatomy 0.000 claims 1
- 208000027129 choroid disease Diseases 0.000 claims 1
- 201000008615 cone dystrophy Diseases 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 201000010206 cystoid macular edema Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 201000006902 exudative vitreoretinopathy Diseases 0.000 claims 1
- 201000006321 fundus dystrophy Diseases 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 208000001786 gonorrhea Diseases 0.000 claims 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 238000013532 laser treatment Methods 0.000 claims 1
- 239000004571 lime Substances 0.000 claims 1
- 230000035168 lymphangiogenesis Effects 0.000 claims 1
- 208000038015 macular disease Diseases 0.000 claims 1
- 208000029233 macular holes Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000002165 neuroretinitis Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 208000008798 osteoma Diseases 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000001297 phlebitis Diseases 0.000 claims 1
- 230000000649 photocoagulation Effects 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- 201000004849 posterior scleritis Diseases 0.000 claims 1
- 201000002267 posterior uveal melanoma Diseases 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 239000000790 retinal pigment Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000005204 segregation Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 238000009736 wetting Methods 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624495P | 2012-04-16 | 2012-04-16 | |
| US61/624,495 | 2012-04-16 | ||
| PCT/US2013/036715 WO2013158597A1 (en) | 2012-04-16 | 2013-04-16 | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015520130A JP2015520130A (ja) | 2015-07-16 |
| JP2015520130A5 true JP2015520130A5 (enExample) | 2016-06-02 |
Family
ID=48183042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507101A Pending JP2015520130A (ja) | 2012-04-16 | 2013-04-16 | ホルミルペプチド受容体２調節物質としての（２−ウレイドアセトアミド）アルキル誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9670150B2 (enExample) |
| EP (1) | EP2838887B1 (enExample) |
| JP (1) | JP2015520130A (enExample) |
| KR (1) | KR20140145203A (enExample) |
| CN (1) | CN104302630A (enExample) |
| AU (1) | AU2013249474A1 (enExample) |
| CA (1) | CA2870356A1 (enExample) |
| ES (1) | ES2711363T3 (enExample) |
| NZ (1) | NZ700733A (enExample) |
| SG (1) | SG11201406629VA (enExample) |
| WO (1) | WO2013158597A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX376348B (es) | 2011-10-26 | 2025-03-07 | Allergan Inc | Derivados de amida de aminoacidos sustituidos con n-urea como moduladores de receptor de tipo peptido receptor de formilo-1 (fprl-1). |
| CA2899804A1 (en) | 2013-03-06 | 2014-09-12 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases |
| AU2014225992B2 (en) | 2013-03-06 | 2018-03-22 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
| EP3071548B1 (en) * | 2013-11-21 | 2017-11-08 | Allergan, Inc. | Phenylcarbamate derivatives as formyl peptide receptor modulators |
| SMT201800061T1 (it) | 2013-11-28 | 2018-05-02 | Kyorin Seiyaku Kk | Derivati dell'urea o loro sali farmacologicamente accettabili utili come io agonisti del recettore del peptide formile di tipo i (fprl-1) |
| WO2015116574A1 (en) * | 2014-01-29 | 2015-08-06 | Allergan, Inc. | Urea hydantoin derivatives as formyl peptide modulators |
| US9663457B2 (en) | 2014-04-09 | 2017-05-30 | Allergan, Inc. | Carbamoyl hydrazine derivatives as formyl peptide modulators |
| CN106458921B (zh) | 2014-05-21 | 2020-03-24 | 阿勒根公司 | 作为甲酰肽受体调节剂的咪唑衍生物 |
| TW201718473A (zh) * | 2015-08-05 | 2017-06-01 | 歐樂根公司 | 作為甲醯肽受體１（ｆｐｒ１）選擇性促效劑之苯基脲類似物 |
| CN109641857A (zh) * | 2016-04-12 | 2019-04-16 | 阿勒根公司 | 作为n-甲酰基肽受体调节剂的苯基脲衍生物 |
| EP3634412A1 (en) * | 2017-06-09 | 2020-04-15 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| KR102615095B1 (ko) * | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 효능제 |
| CN109593067B (zh) * | 2017-09-30 | 2021-11-26 | 暨南大学 | 四氮唑类分子探针化合物或组合物及其应用 |
| EP3762380B1 (en) | 2018-03-05 | 2021-12-15 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2608336A1 (de) * | 1975-03-11 | 1976-09-30 | Sandoz Ag | Neue organische verbindungen, ihre herstellung und verwendung |
| US4291022A (en) | 1975-03-11 | 1981-09-22 | Sandoz Ltd. | Organic compounds |
| JPS57102896A (en) | 1980-12-18 | 1982-06-26 | Grelan Pharmaceut Co Ltd | N-substituted aminophosphonic acid |
| US4521210A (en) | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| JP2697495B2 (ja) * | 1991-06-19 | 1998-01-14 | 富士レビオ株式会社 | アルデヒド誘導体 |
| CA2071621C (en) | 1991-06-19 | 1996-08-06 | Ahihiko Hosoda | Aldehyde derivatives |
| US5686419A (en) | 1994-01-21 | 1997-11-11 | Georgia Tech Research Corp. | Basic α-aminoalkylphosphonate derivatives |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| EP1162194A1 (en) * | 2000-06-06 | 2001-12-12 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
| US7109243B2 (en) * | 2003-03-24 | 2006-09-19 | Irm Llc | Inhibitors of cathepsin S |
| US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| CN100506802C (zh) | 2004-06-04 | 2009-07-01 | 中国科学院上海药物研究所 | 一类甲酰肽样受体-1调节剂、其制备方法和用途 |
| WO2006065755A2 (en) | 2004-12-13 | 2006-06-22 | Glaxo Group Limited | Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists |
| WO2011163502A1 (en) * | 2010-06-24 | 2011-12-29 | Allergan, Inc. | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| AU2014225992B2 (en) * | 2013-03-06 | 2018-03-22 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
| CA2899804A1 (en) * | 2013-03-06 | 2014-09-12 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases |
-
2013
- 2013-04-16 KR KR1020147031783A patent/KR20140145203A/ko not_active Withdrawn
- 2013-04-16 AU AU2013249474A patent/AU2013249474A1/en not_active Abandoned
- 2013-04-16 ES ES13718477T patent/ES2711363T3/es active Active
- 2013-04-16 JP JP2015507101A patent/JP2015520130A/ja active Pending
- 2013-04-16 EP EP13718477.6A patent/EP2838887B1/en active Active
- 2013-04-16 CA CA2870356A patent/CA2870356A1/en not_active Abandoned
- 2013-04-16 SG SG11201406629VA patent/SG11201406629VA/en unknown
- 2013-04-16 WO PCT/US2013/036715 patent/WO2013158597A1/en not_active Ceased
- 2013-04-16 US US13/863,934 patent/US9670150B2/en active Active
- 2013-04-16 NZ NZ700733A patent/NZ700733A/en not_active IP Right Cessation
- 2013-04-16 CN CN201380025558.9A patent/CN104302630A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015520130A5 (enExample) | ||
| JP5917555B2 (ja) | ケモカイン受容体調節因子としてのリン酸誘導体 | |
| JP6181060B2 (ja) | Ｎ−ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体モジュレーターとしてのアリール尿素誘導体 | |
| US9670150B2 (en) | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators | |
| JP2009511632A5 (enExample) | ||
| JP2017043614A5 (enExample) | ||
| CN105228989A (zh) | 黄斑变性治疗中的新颖捕获剂 | |
| JP2014525426A5 (enExample) | ||
| JP2021503449A5 (enExample) | ||
| JP2018514590A5 (enExample) | ||
| JP2016529235A5 (enExample) | ||
| JP2018532692A5 (enExample) | ||
| JP2017520528A (ja) | ホルミルペプチド受容体調節物質としてのイミダゾール誘導体 | |
| JP2017501978A5 (enExample) | ||
| US9868700B2 (en) | Carbamoyl hydrazine derivatives as formyl peptide modulators | |
| WO2015116574A1 (en) | Urea hydantoin derivatives as formyl peptide modulators | |
| KR20120081585A (ko) | 안질환을 치료하기 위한 이소티오졸 | |
| AU2018200226A1 (en) | Benzofuran-2-sulfonamide derivatives as chemokine receptor modulators | |
| AU2012352572A1 (en) | Benzisothiazol-3(1H)-one-5-sulfonyl derivatives as chemokine receptor modulators | |
| JP2013523892A5 (enExample) | ||
| US20150152080A1 (en) | Benzothiophene sulfonamides derivatives as chemokine receptor modulators | |
| JP2014521647A5 (enExample) |